TYRA-300 Shows Early Promise in Metastatic Urothelial Cancer : Oncology Times
An abstract is unavailable.
Related Articles
“Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender Medical group sues over removing “information used every day by health professions” – The Cancer Letter
The web page for the FDA Office of Minority Health and Health Equity is no more. To access this subscriber-only content please log in or…
Nationwide Analysis of Variables Associated With Sarcoid… : JCR: Journal of Clinical Rheumatology
lt sarcoid hospitalizations from 2016 to 2020 National Inpatient Sample database. A univariable screen followed by multivariable analysis was completed to identify predictors of in-hospital…
How blood and bone marrow transplant expertise is changing cancer care at Ohio State
For four decades, Ohio State blood and bone marrow transplant innovation has improved cancer care with an increasing emphasis on patients’ quality of life.
Beyond TKIs: Synthetic Lethal Approaches and Targeted Therapies to Watch in Lung Cancer
Leveraging synthetic lethal approaches in lung cancer with new targets and agents may be a promising avenue of investigation.
Genomic Features May Define Patient Selection in KRAS-mutated NSCLC
Adagrasib elicited higher efficacy in combination with mTOR inhibitors vs alone when treating patients with KRASG12C-mutant non–small cell lung cancer.
Survivorship and Visual Storytelling with Anna Rathkopf
In this episode, host Shikha Jain, MD, speaks with Anna Rathkopf about the mental and physical toll of cancer treatment and survivorship, using photography to…
Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ
This phase 1 nonrandomized clinical trial evaluated the safety and efficacy signaling of combined pembrolizumab and mRNA-2752 to treat patients with high-risk ductal carcinoma in…
Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
The EMA’s CHMP has approved isatuximab in combination with VRd for transplant-ineligible patients with newly diagnosed multiple myeloma.
Endophthalmitis rates after secondary intraocular lens… : Journal of Cataract & Refractive Surgery
Retrospective study. Methods: Medicare FFS beneficiaries who underwent IOL exchange or secondary IOL implantation for preoperative aphakia between January 1, 2011, and November 19, 2022,…
